SINO BIOPHARM (01177) posts a block trade for $26.4M
SINO BIOPHARM (01177) posts a block trade for $26.4M
Market Talk
SINO BIOPHARM (01177) posts a block trade for $26.4M
(Infocast News)
Stock name : SINO BIOPHARM (01177)
Block trade : 1 deal
Price : HK$8.80
Qty : 3M
Turnover : $26.4M
Time Price Qty Turnover
--------------------------------------------------
11:26:20 8.800 3,000,000 26,400,000
* Block Trade: Turnover per trade > HKD $20 million
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) posts a block trade for $23.56M
SINO BIOPHARM (01177) posts a block trade for $23.56M
Market Talk
SINO BIOPHARM (01177) posts a block trade for $23.56M
(Infocast News)
Stock name : SINO BIOPHARM (01177)
Block trade : 1 deal
Price : HK$8.50
Qty : 2.77M
Turnover : $23.56M
Time Price Qty Turnover
--------------------------------------------------
13:05:27 8.500 2,772,000 23,562,000
* Block Trade: Turnover per trade > HKD $20 million
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) posts a block trade for $25.2M
SINO BIOPHARM (01177) posts a block trade for $25.2M
Market Talk
SINO BIOPHARM (01177) posts a block trade for $25.2M
(Infocast News)
Stock name : SINO BIOPHARM (01177)
Block trade : 1 deal
Price : HK$8.40
Qty : 3M
Turnover : $25.2M
Time Price Qty Turnover
--------------------------------------------------
11:03:41 8.400 3,000,000 25,200,000
* Block Trade: Turnover per trade > HKD $20 million
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) posts a block trade for $25.3M
SINO BIOPHARM (01177) posts a block trade for $25.3M
Market Talk
SINO BIOPHARM (01177) posts a block trade for $25.3M
(Infocast News)
Stock name : SINO BIOPHARM (01177)
Block trade : 1 deal
Price : HK$8.11
Qty : 3.12M
Turnover : $25.3M
Time Price Qty Turnover
--------------------------------------------------
09:00:46 8.110 3,120,000 25,303,200
* Block Trade: Turnover per trade > HKD $20 million
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) posts a block trade for $29.9M
SINO BIOPHARM (01177) posts a block trade for $29.9M
Market Talk
SINO BIOPHARM (01177) posts a block trade for $29.9M
(Infocast News)
Stock name : SINO BIOPHARM (01177)
Block trade : 1 deal
Price : HK$7.584
Qty : 3.94M
Turnover : $29.9M
Time Price Qty Turnover
--------------------------------------------------
13:04:59 7.584 3,942,400 29,899,162
* Block Trade: Turnover per trade > HKD $20 million
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) 1H profit up 12.31%; div $0.05
SINO BIOPHARM (01177) 1H profit up 12.31%; div $0.05
Result Ann
SINO BIOPHARM (01177) 1H profit up 12.31%; div $0.05
(Infocast News) Results of Sino Biopharmaceutical Limited (01177) for the first half-year ended 30 June 2025:
Net profit: RMB3.3886B, up 12.31% YoY (RMB3.0172B net profit for the same period last year) Basic EPS: RMB0.1715 Dividend per share proposed: HK$0.05
(WL)
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) posts a block trade for $24M
SINO BIOPHARM (01177) posts a block trade for $24M
Market Talk
SINO BIOPHARM (01177) posts a block trade for $24M
(Infocast News)
Stock name : SINO BIOPHARM (01177)
Block trade : 1 deal
Price : HK$8.00
Qty : 3M
Turnover : $24M
Time Price Qty Turnover
--------------------------------------------------
14:53:26 8.000 3,000,000 24,000,000
* Block Trade: Turnover per trade > HKD $20 million
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) posts a block trade for $26.34M
SINO BIOPHARM (01177) posts a block trade for $26.34M
Market Talk
SINO BIOPHARM (01177) posts a block trade for $26.34M
(Infocast News)
Stock name : SINO BIOPHARM (01177)
Block trade : 1 deal
Price : HK$7.31
Qty : 3.6M
Turnover : $26.34M
Time Price Qty Turnover
--------------------------------------------------
15:34:34 7.310 3,603,000 26,337,930
* Block Trade: Turnover per trade > HKD $20 million
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) posts a block trade for $46.36M
SINO BIOPHARM (01177) posts a block trade for $46.36M
Market Talk
SINO BIOPHARM (01177) posts a block trade for $46.36M
(Infocast News)
Stock name : SINO BIOPHARM (01177)
Block trade : 1 deal
Price : HK$6.885
Qty : 6.73M
Turnover : $46.36M
Time Price Qty Turnover
--------------------------------------------------
15:17:34 6.885 6,733,000 46,356,705
* Block Trade: Turnover per trade > HKD $20 million
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) posts a block trade for $24.58M
SINO BIOPHARM (01177) posts a block trade for $24.58M
Market Talk
SINO BIOPHARM (01177) posts a block trade for $24.58M
(Infocast News)
Stock name : SINO BIOPHARM (01177)
Block trade : 1 deal
Price : HK$6.77
Qty : 3.63M
Turnover : $24.58M
Time Price Qty Turnover
--------------------------------------------------
11:00:25 6.770 3,630,000 24,575,100
* Block Trade: Turnover per trade > HKD $20 million
Back to previous page
Stock Information Provided by Infocast Limited
Disclaimer
Infocast Limited and its information providers endeavor to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Tse, Theresa Y Y (Chairman and Executive Director)
Tse Ping (Senior Deputy Chairman and Executive Director)
Cheng Cheung Ling (Vice Chairman and Executive Director)
Tse Hsin (Vice President and Executive Director)
Tse, Eric S Y (Chief Executive Officer and Executive Director)
Tian Zhoushan (Executive Director)
Li Dakui (Independent Non-Executive Director)
Lu Zhengfei (Independent Non-Executive Director)
Lu Hong (Independent Non-Executive Director)
Zhang Lu Fu (Independent Non-Executive Director)
LI Kwok Tung Donald (Independent Non-Executive Director)
Secretary
Chan Oi Nin Derek
Auditor
Ernst & Young
Address
Unit 09, 41st Floor, Office Tower, Convention Plaza, 1 Harbour Road, Wanchai, Hong Kong
Principally engaged in the research and development, production and sale of a series of modernised Chinese medicines and chemical medicines.
Prospects
China's pharmaceutical industry is currently embracing historic growth opportunities. With the national strategy of innovation-driven development as the guidance, the country's biopharmaceutical innovation capabilities have witnessed significant enhancement, such that the R&D of innovative drugs has evolved from the positioning of the'passive mover'towards the'paralleled player,'or even the'market leader'on the global stage. Chinese innovative drugs not only gains strong momentum for growth in the domestic market, but also steadily makes their presence internationally, thus being widely recognised and becoming an indispensable impetus in the innovative pharmaceutical industry worldwide. As the industry leader, the Group remains deeply committed to four core therapeutic areas-oncology, liver/metabolic diseases, respiratory, and surgery/analgesia. The Group aims to be a leading global pharmaceutical company through delivering innovative therapies for patients.
1. Accelerating Internationalized Deployment
While being firmly rooted in the Chinese market, the Group is expanding its strategic horizon to embrace global opportunities, and leveraging internationalization to accelerate its innovation and development. With a portfolio of globally competitive innovative assets, the Group expects out- licensing to become another source of recurring revenue starting from this year. This will serve as a novel driver for the growth of the Group's performance and unlock the Group's second growth curve with the revenue from internationalization. Looking ahead, the Group will expedite the rollouts of more innovative drugs in global markets, thus enabling the results from innovation in China to benefit patients worldwide and address unmet global clinical needs.
2.
Principal Bankers
Agricultural Bank of China Limited
Bank of China (Hong Kong) Limited
The HongKong and Shanghai Banking Corporation Limited
Registry
Tricor Investor Services Ltd.
17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong
Major Shareholders
Tse, Eric S Y (21.61%)
Cheng Cheung Ling (15.82%)
Tse Ping (9.00%)
Share Placement
Announcement Date
No. of Placing Shares
Price ($)
Announcement Date
N/A
No. of Placing Shares
N/A
Price ($)
N/A
Share Repurchase
Repurchase Date
Repurchase Amount
Highest Price ($)
Lower Price ($)
Repurchase Date
2025-04-09
Repurchase Amount
4,000,000
Highest Price ($)
3.420
Lower Price ($)
3.190
Repurchase Date
2025-04-08
Repurchase Amount
5,000,000
Highest Price ($)
3.420
Lower Price ($)
3.320
Repurchase Date
2025-01-16
Repurchase Amount
3,500,000
Highest Price ($)
2.810
Lower Price ($)
2.790
Repurchase Date
2025-01-14
Repurchase Amount
5,000,000
Highest Price ($)
2.890
Lower Price ($)
2.850
Repurchase Date
2025-01-10
Repurchase Amount
7,000,000
Highest Price ($)
2.920
Lower Price ($)
2.850
Financial Record
Profit & Loss Account
2024-12-31 (HK$M)
2023-12-31 (HK$M)
2022-12-31 (HK$M)
2021-12-31 (HK$M)
Turnover
Operating Profit
Exception Items
Pre-Tax Profit / Loss
Net Profit / Loss
Earnings Per Share (¢)
Dividend Per Share (¢)
P / E (x)
Dividend Yield (%)
2024-12-31 (HK$M)
Turnover
30,755.83
Operating Profit
7,878.19
Exception Items
N/A
Pre-Tax Profit / Loss
7,438.52
Net Profit / Loss
3,722.07
Earnings Per Share (¢)
20.35
Dividend Per Share (¢)
7.00
P / E (x)
15.73
Dividend Yield (%)
2.19
2023-12-31 (HK$M)
Turnover
30,842.09
Operating Profit
7,682.72
Exception Items
N/A
Pre-Tax Profit / Loss
6,539.99
Net Profit / Loss
2,570.26
Earnings Per Share (¢)
13.87
Dividend Per Share (¢)
5.00
P / E (x)
25.01
Dividend Yield (%)
1.44
2022-12-31 (HK$M)
Turnover
32,268.60
Operating Profit
7,142.76
Exception Items
N/A
Pre-Tax Profit / Loss
6,478.97
Net Profit / Loss
2,851.85
Earnings Per Share (¢)
15.31
Dividend Per Share (¢)
12.00
P / E (x)
29.84
Dividend Yield (%)
2.63
2021-12-31 (HK$M)
Turnover
32,854.12
Operating Profit
6,421.89
Exception Items
N/A
Pre-Tax Profit / Loss
22,716.24
Net Profit / Loss
17,867.55
Earnings Per Share (¢)
95.20
Dividend Per Share (¢)
8.00
P / E (x)
5.74
Dividend Yield (%)
1.47
Balance Sheet
2024-12-31 (HK$M)
2023-12-31 (HK$M)
2022-12-31 (HK$M)
2021-12-31 (HK$M)
Current Assets
Non-current Assets
Total Assets
Current Liabilities
Non-current Liabilities
Total Liabilities
Total Equity
2024-12-31 (HK$M)
Current Assets
26,252.85
Non-current Assets
43,308.63
Total Assets
69,561.48
Current Liabilities
20,798.33
Non-current Liabilities
3,272.93
Total Liabilities
24,071.26
Total Equity
45,490.22
2023-12-31 (HK$M)
Current Assets
26,238.46
Non-current Assets
43,866.78
Total Assets
70,105.23
Current Liabilities
24,917.19
Non-current Liabilities
3,117.12
Total Liabilities
28,034.31
Total Equity
42,070.92
2022-12-31 (HK$M)
Current Assets
29,078.22
Non-current Assets
42,750.66
Total Assets
71,828.88
Current Liabilities
22,592.94
Non-current Liabilities
6,693.63
Total Liabilities
29,286.57
Total Equity
42,542.31
2021-12-31 (HK$M)
Current Assets
28,746.74
Non-current Assets
45,303.82
Total Assets
74,050.56
Current Liabilities
18,768.49
Non-current Liabilities
9,135.69
Total Liabilities
27,904.19
Total Equity
46,146.37
Financial Ratios
2024-12-31
2023-12-31
2022-12-31
2021-12-31
Return On Asset (ROA)
Return On Equity (ROE)
Net Profit Margin
Gross Profit Margin
Debt To Equity Ratio
Asset To Equity Ratio
Current Ratio (x)
P / E (x)
Dividend Yield (%)
2024-12-31
Return On Asset (ROA)
5.35
Return On Equity (ROE)
8.18
Net Profit Margin
12.10
Gross Profit Margin
25.62
Debt To Equity Ratio
52.92
Asset To Equity Ratio
152.92
Current Ratio (x)
1.26
P / E (x)
15.73
Dividend Yield (%)
2.19
2023-12-31
Return On Asset (ROA)
3.67
Return On Equity (ROE)
6.11
Net Profit Margin
8.33
Gross Profit Margin
24.91
Debt To Equity Ratio
66.64
Asset To Equity Ratio
166.64
Current Ratio (x)
1.05
P / E (x)
25.01
Dividend Yield (%)
1.44
2022-12-31
Return On Asset (ROA)
3.97
Return On Equity (ROE)
6.70
Net Profit Margin
8.84
Gross Profit Margin
22.14
Debt To Equity Ratio
68.84
Asset To Equity Ratio
168.84
Current Ratio (x)
1.29
P / E (x)
29.84
Dividend Yield (%)
2.63
2021-12-31
Return On Asset (ROA)
24.13
Return On Equity (ROE)
38.72
Net Profit Margin
54.38
Gross Profit Margin
19.55
Debt To Equity Ratio
60.47
Asset To Equity Ratio
160.47
Current Ratio (x)
1.53
P / E (x)
5.74
Dividend Yield (%)
1.47
Dividend History
Dividend History
Year End:
2024-12-31
Announce Date
Ex-Date
Payable Date
Amount (¢)
Type
Announce Date
N/A
Ex-Date
2025-08-29
Payable Date
2025-09-23
Amount (¢)
5.00
Type
Interim
Announce Date
N/A
Ex-Date
2025-06-16
Payable Date
2025-07-10
Amount (¢)
4.00
Type
Final
Announce Date
N/A
Ex-Date
2024-09-10
Payable Date
2024-10-04
Amount (¢)
3.00
Type
Interim
Announce Date
N/A
Ex-Date
2024-06-11
Payable Date
2024-07-05
Amount (¢)
3.00
Type
Final
Announce Date
N/A
Ex-Date
2023-10-04
Payable Date
2023-10-27
Amount (¢)
2.00
Type
Interim
Announce Date
N/A
Ex-Date
2023-06-20
Payable Date
2023-07-18
Amount (¢)
6.00
Type
Final
Capital Changes
Ex-Date
Type
Ex-Date
N/A
Type
N/A
Description
Description
N/A
App Download
Instant trading of stocks after taking an in-depth look at every move of the market
Website Push Notifications
Provide the latest financial news and promotions
Subscribe to keep up to date with CHIEF
Informative contents include:
Latest news, coming seminar, featured articles on wealth management
Stock Information Provided by Infocast Limited
1
